Key result
Review evaluates interleukin-1 as a heart failure biomarker and discusses recombinant IL-1R therapy.
Why the study?
Inflammatory reactions in heart failure damage cardiomyocytes and drive myocardial remodeling, warranting an evaluation of IL-1 as a clinical marker and therapeutic target.
Does treatment with a recombinant form of IL-1R affect the course of the disease in patients with heart failure?
Does treatment with a recombinant form of IL-1R affect the course of the disease in patients with heart failure?
This review highlights the potential of IL-1 as a diagnostic and prognostic marker in heart failure and discusses the therapeutic effects of recombinant IL-1R.
Inflammation is a universal response of a living organism to various damaging factors and is aimed at restoring tissue integrity and minimizing cell death. Proinflammatory cytokines, in particular interleukins, are active participants in the inflammatory response. In patients with heart failure, inflammatory reactions lead to damage to cardiomyocytes, their apoptosis and activation of neurohumoral systems, which contribute to the initiation of myocardial hibernation and mechanisms of its remodeling. The purpose of this review is to consider IL-1 as a diagnostic and prognostic marker in heart failure, as well as the effect of treatment with a recombinant form of IL-1R on the course of the disease.
No takes yet. Share an insight, caveat, or question.
Alieva et al. (2022) conducted a review in Heart failure. Interleukin-1 and recombinant IL-1R was evaluated. This review evaluates interleukin-1 as a diagnostic and prognostic marker in heart failure and discusses the therapeutic effects of a recombinant form of IL-1R on disease progression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: